Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

Phase 1/2 Completed 13 enrolled University of North Carolina, Chapel Hill Genentech, Inc. · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.

Timeline

Start: 2009-07
Primary completion: 2015-08
Completion: 2015-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Omalizumab	Monoclonal antibody	—	Subcutaneous
Comparator	Peanut Flour	Protein / enzyme biologic	8000 mg	Oral

Indications

No indication recorded.